Project Image:
Title of the project:
The Multiplex Immunoassays group at the NMI will measure samples from the MuSPAD seroprevalence study with their MULTICOV-AB assay.
Project leader:
Dr. Nicole Schneiderhan-Marra
Project funding:
  • Helmholtz
Funding reference number:

MuSPAD (Multi-local and serial cross-sectional prevalence study on antibodies against SARS-CoV-2 in Germany) is a planned study led by the Helmholtz Centre for Infection Research to assess the actual seroprevalence of SARS-CoV-2 within the population. Since the initial outbreak of SARS-CoV-2 in late 2019, scientific data has indicated that a large proportion of those infected show no typical symptoms of the disease and are therefore not recorded in the reporting statistics. As a result, the actual case number, the immunity towards SARS-CoV-2 and the mortality rate are unknown. Knowledge on these parameters is required in order to accurately assess the further course of the pandemic in Germany. In order to determine the spread of the virus, blood serum will be collected and tested for antibodies against SARS-CoV-2. These antibodies are formed shortly after infection by the immune system and remain even after the illness has passed, enabling them to react faster and more efficiently in the event of a secondary infection. How long immunity against SARS-CoV-2 lasts remains unclear and will be evaluated as part of this study.

Project partners:
  • Helmholtz Institute for Infection Research